Monitor FDA pre-submission meetings and any announced BLA timeline. The agreement strengthens ImmunityBio's BCG supply position, but regulatory approval is not guaranteed. Watch for Data Use Agreement with SWOG/NCI to support BLA.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 19 $7.76entry
- T+1 · 6mo ago +3.74%α +2.70% · $8.05
- T+5 · 6mo ago +2.26%α +0.01% · $7.94
- T+20 · 5mo ago −9.92%α −10.91% · $6.99
- T+60 · 3mo ago −1.42%α −7.71% · $7.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strain of BCG, securing a second potential source of BCG for bladder cancer treatment. The agreement provides exclusive U.S. rights with no upfront payment, and ImmunityBio will lead regulatory submissions and commercialization. Positive Phase III data from the SWOG S1602 trial supports non-inferiority versus TICE BCG, but the product remains investigational in the U.S.
Key Financial Metrics
Key Facts
- Exclusive U.S. development and supply agreement with Japan BCG Laboratory for Tokyo-172 BCG.
- No upfront or milestone payments; all vials for regulatory submission provided at no cost.
- ImmunityBio is sole BLA applicant and marketing authorization holder; 10-year term from FDA approval.
- SWOG S1602 Phase III trial demonstrated non-inferiority of Tokyo-172 BCG vs TICE BCG (HR 0.82, 95.8% CI 0.63-1.08).
- ImmunityBio now has two potential BCG sources: this agreement and ongoing partnership with Serum Institute of India for rBCG.
Financial Impact
No financial terms disclosed; no upfront payment. Potential future revenue stream if FDA-approved, but magnitude uncertain.
Risk Factors
- Tokyo-172 BCG is not FDA-approved; regulatory pathway uncertain.
- Competition from existing BCG products and other intravesical therapies.
- Reliance on JBL for manufacturing; supply chain risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-229153 |
| Document: d75270dex991.htm | 0001193125-26-229153 |
| Document: 0001193125-26-229153-index-headers.html | 0001193125-26-229153 |
| Document: 0001193125-26-229153-index.html | 0001193125-26-229153 |
| Document: 0001193125-26-229153.txt | 0001193125-26-229153 |
Track record
11 reports on IBRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
- Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
- Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
- Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
- May 18, 202626w ago 8-K Bullish 5/10 Viewing Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
- Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
- Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers